{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:41:53Z","timestamp":1764225713604,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"am","delay-in-days":465,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clinthera.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T07:12:05Z","timestamp":1621840325000},"page":"1116-1124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aminoglycosides in Critically Ill Septic Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: A Multicenter, Observational Study"],"prefix":"10.1016","volume":"43","author":[{"given":"Alexandre","family":"Boyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kada","family":"Klouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Canet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy-nga","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Boh\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Orieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Lautrette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Gruson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Souweine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.04.011_bib0001","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00134-009-1635-9","article-title":"Evaluation of \"Loss\" and \"End stage renal disease\" after acute kidney injury defined by the Risk, Injury, Failure, Loss and ESRD classification in critically ill patients","volume":"35","author":"Cartin-Ceba","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0002","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Bagshaw","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0003","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1128\/AAC.03750-14","article-title":"Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock","volume":"28","author":"Picard","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0004","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2710.2008.00947.x","article-title":"Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance","volume":"33","author":"Fukuoka","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0006","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0007","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/444500","article-title":"Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy","volume":"41","author":"Trotman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0008","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1128\/AAC.00828-16","article-title":"Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy","volume":"60","author":"Roger","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0009","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ijantimicag.2011.01.026","article-title":"Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy","volume":"37","author":"Taccone","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0010","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1128\/AAC.01758-10","article-title":"Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration","volume":"55","author":"Yamamoto","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0011","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1164\/rccm.201408-1431OC","article-title":"Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial","volume":"191","author":"Souweine","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0012","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.35.10.1953","article-title":"Antibiotic Tissue Penetration and Its Relevance: Impact of Tissue Penetration on Infection Response","volume":"35","author":"Nix","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0013","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40264-013-0031-0","article-title":"Aminoglycosides in septic shock. An Overview, with specific consideration given to their nephrotoxic risk","volume":"36","author":"Boyer","year":"2013","journal-title":"Drug safety"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0014","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0b013e31818b6b2f","article-title":"Suboptimal aminoglycoside dosing in critically ill patients","volume":"30","author":"Rea","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF01712162","article-title":"Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient","volume":"22","author":"Botha","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0016","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00005373-200011000-00013","article-title":"Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens","volume":"49","author":"Barletta","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0017","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1128\/AAC.00374-11","article-title":"Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration","volume":"55","author":"Akers","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.04.011_bib0018","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00134-014-3276-x","article-title":"Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen","volume":"40","author":"de Montmollin","year":"2014","journal-title":"Intensive Care Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:01Z","timestamp":1758963301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182100206X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S014929182100206X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminoglycosides in Critically Ill Septic Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: A Multicenter, Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}